Analyst Reco. Liquidia Corporation

Equities

LQDA

US53635D2027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
12.53 ^USD	+1.29%		-5.72%	+4.16%

Apr. 01	Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	MT
Apr. 01	Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing	Mar. 20	MT
HC Wainwright Adjusts Price Target on Liquidia to $32 From $16, Maintains Buy Rating	Mar. 14	MT
BofA Securities Raises Price Target on Liquidia to $15 From $13, Maintains Buy Rating	Dec. 21	MT
Needham Adjusts Price Target on Liquidia to $18 From $16, Maintains Buy Rating	23-03-17	MT
Needham Raises Liquidia's Price Target to $16 From $12, Maintains Buy Rating	22-09-01	MT
Wedbush Lowers Liquidia to Underperform From Neutral, Price Target to $3 From $4 on Adjusted Yutrepia Timeline	22-09-01	MT
Ladenburg Thalmann Initiates Coverage of Liquidia at Buy with $15 Price Target	22-07-22	MT
BTIG Adjusts Liquidia's Price Target to $17 From $14, Reiterates Buy Rating	22-07-20	MT
BTIG Starts Liquidia at Buy With $14 Price Target	22-05-31	MT
BofA Securities Starts Liquidia at Buy With $12 Price Target	22-05-26	MT
Wedbush Cuts Price Target on Liquidia Technologies to $4 From $6, Following Tyvaso Regulatory Update, Maintains Neutral Rating	22-05-24	MT
Wedbush Cuts Price Target on Liquidia Technologies to $4 From $6, Citing Tyvaso Market Penetration Estimates, Maintains Neutral Rating	22-05-24	MT
HC Wainwright Adjusts Liquidia Technologies' Price Target to $16 From $6, Keeps Buy Rating	22-02-03	MT
Needham Adjusts Liquidia Technologies' Price Target to $12 from $8, Keeps Buy Rating	22-01-10	MT
Wedbush Lifts Liquidia Technologies' Price Target to $6 From $2; Neutral Rating Kept	21-11-09	MT
LIQUIDIA : Wedbush Adjusts Price Target for Liquidia Technologies to $2 From $3, Maintains Neutral Rating	21-05-13	MT
LIQUIDIA : Wedbush Adjusts Liquidia Technologies' PT to $3 From $2, Citing Subcutaneous Treprostinil for Pulmonary Arterial Hypertension; Neutral Rating Kept	21-03-31	MT
LIQUIDIA : Wedbush Adjusts Price Target on Liquidia Technologies to $2 From $4 on Lowered LIQ861/PAH Penetration Rate Estimates; Neutral Rating Kept	21-03-30	MT
LIQUIDIA : HC Wainwright Initiates Liquidia Technologies at Buy With $6 Price Target	20-12-04	MT
LIQUIDIA : Wedbush Cuts Liquidia Technologies to Neutral From Outperform on LIQ861 Regulatory Headwind, LIQ865 US Launch Timeline; PT to $4 From $20	20-11-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Liquidia Corporation

Equities

LQDA

US53635D2027

Analyst Reco.

Filters